Floatz logo

TACROLIMUS

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue

University of Medicine and Dentistry of New JerseySmall moleculePhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
81/ 100

Competitive context

36 Active assets in the Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
SWOG Cancer Research Network
Phase 2BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
City of Hope Medical Center
Phase 3BBB
DEXAMETHASONE
Izidore Lossos, MD
Phase 2BBB
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BB
Fludarabine
UNC Lineberger Comprehensive Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

TACROLIMUS is also rated in:

disease related to transplantationDormant
BBB
Indicative ·
79 / 100
View asset →
disease related to solid organ transplantationDormant
BBB
Indicative ·
76 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →